Skip to main content
Equibles
RNAC logo

RNAC · Cartesian Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track RNAC — free

Use RNAC with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RNAC.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.18 -0.23 (-3.59%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$193.94M
Shares
30.26M
Volume · Oct 23 85.81K Avg daily vol (3M) 131.68K

Cartesian Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Cartesian Therapeutics, Inc. (RNAC), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-05-19
Cartesian Therapeutics, Inc. (RNAC) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-04-13
Cartesian Therapeutics, Inc. (RNAC) April 13, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q1
2025-05-08
Cartesian Therapeutics, Inc. (RNAC) Q1 2025 Earnings Call Transcript
Confident tone Pipeline expansion into myositis Safety profile advantage vs. DNA CAR-Ts Lead Asset Descartes-8 in Myasthenia Gravis
Revenue
$1.10M
▼ 81.2% YoY
Diluted EPS
$-0.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-17
Cartesian Therapeutics, Inc. (RNAC) Q2 2023 Earnings Call
Revenue
$5.25M
▼ 86.6% YoY
Diluted EPS
$-2.23
▼ 223.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-11-03
Cartesian Therapeutics, Inc. (RNAC) Q3 2022 Earnings Call
Revenue
$20.71M
▼ 15.2% YoY
Diluted EPS
$-1.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Cartesian Therapeutics, Inc. (RNAC) Q2 2022 Earnings Call
Revenue
$39.27M
▲ 99.7% YoY
Diluted EPS
$1.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Cartesian Therapeutics, Inc. (RNAC) Q1 2022 Earnings Call
Revenue
$34.00M
▲ 207.7% YoY
Diluted EPS
$2.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Cartesian Therapeutics, Inc. (RNAC) Q4 2021 Earnings Call
Revenue
$29.94M*
▲ 150.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Cartesian Therapeutics, Inc. (RNAC) Q3 2021 Earnings Call
Revenue
$24.43M
▲ 425.8% YoY
Diluted EPS
$-4.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Cartesian Therapeutics, Inc. (RNAC) Q2 2021 Earnings Call
Revenue
$19.66M
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Cartesian Therapeutics, Inc. (RNAC) Q1 2021 Earnings Call
Revenue
$11.05M
Diluted EPS
$-6.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Cartesian Therapeutics, Inc. (RNAC) Q4 2020 Earnings Call
Revenue
$11.95M*
▲ 79.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Cartesian Therapeutics, Inc. (RNAC) Q3 2020 Earnings Call
Revenue
$4.65M
Diluted EPS
$-2.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Cartesian Therapeutics, Inc. (RNAC) Q2 2020 Earnings Call
Revenue
$0
▼ 100% YoY
Diluted EPS
$-7.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Cartesian Therapeutics, Inc. (RNAC) Q1 2020 Earnings Call
Revenue
$0
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Cartesian Therapeutics, Inc. (RNAC) Q4 2019 Earnings Call
Revenue
$6.65M
▲ 636.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–16 of 16 webcasts
Key facts CIK 1453687 CUSIP 816212302 13F (30d) 12 filings 12 filers Visit website Investor relations